BLAS
GIL EXTREMERA
Ikertzailea 2018-2019 tartean
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoGlaxoSmithKline (United Kingdom)-ko ikertzaileekin lankidetzan egindako argitalpenak (3)
2016
2003
-
Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension
International Journal of Clinical Practice, Vol. 57, Núm. 4, pp. 273-279
-
The adjunctive of effect of telmisartan in patients with hypertension uncotrolled on current antihypertensive therapy
International Journal of Clinical Practice, Vol. 57, Núm. 10, pp. 861-866